Descripción del proyecto
Anticuerpos monoclonales contra la COVID-19
La experiencia previa sobre los coronavirus SARS y MERS está resultando fundamental para el desarrollo rápido de nuevas estrategias de diagnóstico, profilácticas y de intervención terapéutica contra la COVID-19. El proyecto financiado con fondos europeos MANCO se basa en la tecnología generada durante el proyecto en curso ZAPI, financiado por la Iniciativa sobre medicamentos innovadores (IMI), sobre anticuerpos monoclonales contra los coronavirus. Los investigadores de MANCO identificarán anticuerpos monoclonales específicos contra el nuevo coronavirus y los validarán a nivel preclínico. La idea es hacer avanzar una molécula de partida de un anticuerpo monoclonal profiláctico y/o terapéutico hacia un ensayo clínico de fase I y publicar los resultados en un plazo de dos años desde el inicio del proyecto.
Objetivo
"Lessons learned from, and intervention efforts against SARS coronavirus (CoV), MERS-CoV and other emerging viruses provide invaluable information to accelerate the coordinated response against 2019 novel (2019 -n)CoV and the rapid development and manufacture of new diagnostic, prophylactic and therapeutic intervention strategies. A -promising approach to both patient management of emerging viral infections and to better preparedness and response to emerging epidemics is the use of monoclonal antibodies. MANCO aims at contributing to the rapid international response against 2019-nCoV, through preclinical and clinical evaluation of monoclonal antibodies against 2019-nCoV. MANCO will build on and leverage outstanding results from ongoing IMI-funded project #115760 ZAPI, including recently-discovered broadly cross-reactive H2L2 monoclonal antibodies against betacoronaviruses and an established pipeline for rapid identification of specific H2L2 monoclonal antibodies against 2019-nCoV; antibodies that will be selected to proceed to GMP manufacturing in high-yield CHO cell-lines. This project furthermore builds on ZAPI consortium’s experience and expertise for the development and establishment of relevant animal models, to ensure preclinical efficacy and safety, including absence of antibody-dependent enhancement, an issue seen to occur in some immunization studies against feline and SARS CoVs. Based on the generated preclinical data, MANCO will advance one lead (prophylactic and/or therapeutic) monoclonal antibody into a Phase I clinical trial that can be completed within two years of the start of the project, by leveraging clinical expertise, infrastructure and network currently in place for ongoing CEPI-funded projects on candidate vaccines against MERS-CoV (#INID1801) and Rift Valley Fever virus (#INLA1901), and H2020-funded projects on improved vaccines targeting the elderly (ISOLDA #848166) and on universal influenza vaccines, including in LMICs (ENDFLU #874650)."
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
H2020-SC1-PHE-CORONAVIRUS-2020
Consulte otros proyectos de esta convocatoriaRégimen de financiación
RIA - Research and Innovation actionCoordinador
3015 GD Rotterdam
Países Bajos